Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-01-11
2011-01-11
Landsman, Robert (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S308000, C530S391100, C530S391900
Reexamination Certificate
active
07867972
ABSTRACT:
The invention provides fusion proteins comprising an exendin-4 fused to a transferrin (Tf) via a polypeptide linker, as well as corresponding nucleic acid molecules, vectors, host cells, and pharmaceutical compositions. The invention also provides the use of the exendin-4/Tf fusion proteins for treatment of Type II diabetes, obesity, and to reduce body weight.
REFERENCES:
patent: 4289689 (1981-09-01), Friesen et al.
patent: 4738931 (1988-04-01), Sugano et al.
patent: 4816449 (1989-03-01), Hahn
patent: 5026651 (1991-06-01), Bowman et al.
patent: 5091513 (1992-02-01), Huston et al.
patent: 5262177 (1993-11-01), Brown et al.
patent: 5424286 (1995-06-01), Eng
patent: 5432018 (1995-07-01), Dower et al.
patent: 5442043 (1995-08-01), Fukuta et al.
patent: 5455030 (1995-10-01), Ladner et al.
patent: 5464933 (1995-11-01), Bolognesi et al.
patent: 5518889 (1996-05-01), Ladner et al.
patent: 5545618 (1996-08-01), Buckley et al.
patent: 5571691 (1996-11-01), Conneely et al.
patent: 5571896 (1996-11-01), Conneely et al.
patent: 5656272 (1997-08-01), Le et al.
patent: 5672683 (1997-09-01), Friden et al.
patent: 5817789 (1998-10-01), Heartlein et al.
patent: 5876969 (1999-03-01), Fleer et al.
patent: 5925351 (1999-07-01), Browning et al.
patent: 5948613 (1999-09-01), Teng et al.
patent: 5977307 (1999-11-01), Friden et al.
patent: 5986067 (1999-11-01), Funk et al.
patent: 6027921 (2000-02-01), Heartlein et al.
patent: 6066469 (2000-05-01), Kruzel et al.
patent: 6069193 (2000-05-01), Vargas et al.
patent: 6191102 (2001-02-01), DiMarchi et al.
patent: 6245737 (2001-06-01), Boyd et al.
patent: 6262026 (2001-07-01), Heartlein et al.
patent: 6277817 (2001-08-01), Kruzel et al.
patent: 6329336 (2001-12-01), Bridon et al.
patent: 6348568 (2002-02-01), Barney et al.
patent: 6380362 (2002-04-01), Watson et al.
patent: 6420346 (2002-07-01), Karin
patent: 6455687 (2002-09-01), Kruzel et al.
patent: 6458924 (2002-10-01), Knudsen et al.
patent: 6583111 (2003-06-01), DiMarchi et al.
patent: 6723530 (2004-04-01), Drucker
patent: 6825037 (2004-11-01), Funk et al.
patent: 6858576 (2005-02-01), Young et al.
patent: 6956026 (2005-10-01), Beeley et al.
patent: 6998387 (2006-02-01), Goke et al.
patent: 7067133 (2006-06-01), Nicolau
patent: 7176278 (2007-02-01), Prior
patent: 7285526 (2007-10-01), Maroun
patent: 2001/0025026 (2001-09-01), Heartlein et al.
patent: 2002/0049153 (2002-04-01), Bridon et al.
patent: 2003/0199672 (2003-10-01), Knudsen et al.
patent: 2003/0221201 (2003-11-01), Prior et al.
patent: 2003/0226155 (2003-12-01), Sadeghi et al.
patent: 2003/0232754 (2003-12-01), Holst et al.
patent: 2003/0235884 (2003-12-01), Cummings et al.
patent: 2004/0023334 (2004-02-01), Prior
patent: 2004/0053370 (2004-03-01), Glaesner et al.
patent: 2005/0054043 (2005-03-01), Funk et al.
patent: 2006/0105387 (2006-05-01), Prior et al.
patent: 2006/0130158 (2006-06-01), Turner et al.
patent: 2006/0205037 (2006-09-01), Sadeghi et al.
patent: 2007/0060512 (2007-03-01), Sadeghi et al.
patent: 0 314 317 (1989-05-01), None
patent: 0 413 662 (1991-02-01), None
patent: 0 978 565 (2000-02-01), None
patent: 1 408 050 (2004-04-01), None
patent: 91/09967 (1991-07-01), None
patent: 95/02421 (1995-01-01), None
patent: 99/43707 (1999-02-01), None
patent: 99/46283 (1999-09-01), None
patent: 00/69911 (2000-11-01), None
patent: 01/04156 (2001-01-01), None
patent: 01/36643 (2001-05-01), None
patent: 01/46254 (2001-06-01), None
patent: 01/79258 (2001-10-01), None
patent: 02/46227 (2002-06-01), None
patent: 03/016349 (2003-02-01), None
patent: 03/020746 (2003-03-01), None
patent: 03/082898 (2003-10-01), None
patent: 2004/019872 (2004-03-01), None
patent: 2004/020404 (2004-03-01), None
patent: 2004/020405 (2004-03-01), None
patent: 2004/020454 (2004-03-01), None
patent: 2004/020588 (2004-03-01), None
patent: 2004/078777 (2004-09-01), None
patent: 2005/021579 (2005-03-01), None
patent: 2006/017688 (2006-02-01), None
patent: 2006/049983 (2006-05-01), None
patent: 2006/096515 (2006-09-01), None
McGinnis and Foege, “Actual causes of death in the United States”, JAMA, 270(18):2207-2212, 1993.
Parkes et al., “Insulinotropic Actions of Exendin-4 and Glucagon-Like Peptide-1 In Vivo and In Vitro”, Metabolism, 50 (5):583-589, 2001 .
Aziz and Anderson, “Exendin-4, a GLP-1 Receptor Agonist, Modulates the Effect of Macronutrients on Food Intake by Rats”, The Journal of Nutrition, 132:990-995, 2002.
Egan et al., “The Insulinotropic Effect of Acute Exendin-4 Administered to Humans: Comparison of Nondiabetic State to Type 2 Diabetes”, The Journal of Clinical Endocrinology & Metabolism, 87(3):1282-1290, 2002.
Kolterman et al., “Synthetic Exendin-4 (Exenatide) Significantly Reduces Postprandial and Fasting Plasma Glucose in Subjects with Type 2 Diabetes”, The Journal of Clinical Endocrinology & Metabolism, 88(7):3082-3089, 2003.
Fineman et al., “Effect on Glycemic Control of Exenatide (Synthetic Exendin-4) Additive to Existing Metformin and/or Sulfonylurea Treatment in Patients With Type 2 Diabetes”, Diabetes Care, 26(8):2370-2377, 2003.
PCT International Search Report, PCT/IB2007/002047.
Egan et al., “Glucagon-like peptide-1, fused to human transferrin, is a long-acting and potent anti-hyperglycemic agent”, Diabetologia, 48(Suppl.1):A202, 2005, abstract 548.
U.S. Appl. No. 11/659,222, filed Aug. 3, 2005.
Arndt, “Carbohydrate-deficient Transferrin as a Marker of Chronic Alcohol Abuse: A Critical Review of Preanalysis, Analysis, and Interpretation”, Clinical Chemistry, 47(1):13-27, 2001.
Ali et al., “Transferrin Trojan Horses as a Rational Approach for the Biological Delivery of Therapeutic Peptide Domains”, J. Biol. Chem., 274(34):24066-24073, 1999.
Newton et al., “Antitransferrin receptor antibody-RNase fusion protein expressed in the mammary gland of transgenic mice”, Journal of Immunological Methods, 231:159-167, 1999 .
Park et al., “Production and Characterization of Fusion Proteins Containing Transferrin and Nerve Growth Factor”, Journal of Drug Targeting, 6(1):53-64, 1998.
Prince et al., “Efficient Endocytosis of the Cystic Fibrosis Transmembrane Conductance Regulator Requires a Tyrosine-based Signal”, The Journal of Biological Chemistry, 274(6):3602-3609, 1999.
Regoeczi et al., “Rat Aglycotransferrin and Human Monoglycotransferrin: Production and Metabolic Properties”, Archives of Biochemistry and Biophysics, 268(2):637-642, 1989.
Shin et al., “Transferrin-antibody fusion proteins are effective in brain targeting”, Proc. Natl. Acad. Sci. USA, 92 (7):2820-2824, 1995.
Xia et al., “Hypoglycemic Effect of Insulin-Transferrin Conjugate in Streptozotocin-Induced Diabetic Rats”, The Journal of Pharmacology and Experimental Therapeutics, 295(2):594-600, 2000.
Database A—GENESEQ (Compugen LTD), Accession No. AAR66492, (Jacobs et al), Nov. 25, 1994.
Gallwitz et al., “GLP-1/GIP chimeric peptides define the structural requirements for specific ligand-receptor interaction of GLP-1”, Regulatory Peptides, 63(1):17-22, 1996 .
Aldred et al., “Synthesis of rat transferrin inEscherichia colicontaining a recombinant bacteriophage”, Biochemical and Biophysical Research Communications, 122(3):960-965, 1984.
Adrian et al., “Human transferrin. Expression and iron modulation of chimeric genes in transgenic mice”, The Journal of Biological Chemistry, 265(22):13344-13350, 1990.
MacGillivray et al., “The Primary Structure of Human Serum Transferrin. The structures of seven cyanogen bromide fragments and the assembly of the complete structure”, The Journal of Biological Chemistry, 258 (6):3543-3553, 1983.
Salmon et al., “Production of Human Lactoferrin in Transgenic Tobacco Plants”, Protein Expression and Purification, 13:127-135, 1998.
Ward et al., “A System for Production of Commercial Quantities of Human Lactoferrin: A Broad Spectrum Natural Antibiotic”, Bio/Technology, 1
Ballance David James
Prior Christopher P.
Sadeghi Homayoun
Turner Andrew J.
Chandra Gyan
Gumbleton Timothy J.
Landsman Robert
Martin Deborah A.
Pharmacia & Upjohn Company LLC
LandOfFree
Fusion protein of exendin-4 to a transferrin (Tf) polypeptide does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fusion protein of exendin-4 to a transferrin (Tf) polypeptide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fusion protein of exendin-4 to a transferrin (Tf) polypeptide will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2729447